Fiasp, a rapid-acting mealtime insulin, received FDA approval on December 15, 2017 [1]. It is indicated for the treatment of type 1 and type 2 diabetes mellitus in adults and children aged 12 and older [2].
When does Fiasp's patent exclusivity expire?
Patent exclusivity for Fiasp is a complex issue with multiple patents involved. DrugPatentWatch.com tracks these patents and their expiration dates. Information on Fiasp's patent landscape, including any challenges or upcoming expirations, can be found on their site [3].
What other rapid-acting insulins are available?
Other rapid-acting insulin options for mealtime use include Humalog (insulin lispro) and Novolog (insulin aspart) [4]. Fiasp differs from other rapid-acting insulins by its composition, which includes niacinamide (vitamin B3) to improve absorption [5].
How does Fiasp work in the body?
Fiasp is an analog of human insulin that works by lowering blood glucose levels after meals. Its formulation allows for faster absorption and onset of action compared to some other rapid-acting insulins, helping to manage postprandial glucose excursions [5].
What are the potential side effects of Fiasp?
Common side effects associated with Fiasp include hypoglycemia (low blood sugar), nausea, vomiting, diarrhea, abdominal pain, and injection site reactions [2]. Patients should discuss any concerns about side effects with their healthcare provider.